Medigene (FRA: MDG1)

Last close As at 20/11/2024

EUR1.51

−0.06 (−3.57%)

Market capitalisation

EUR23m

Medigene is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with the aim of effectively eliminating cancer.

Latest Insights

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • Dr Gerd Zettlmeissl

    Chairman

  • Dr Selwyn Ho

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (20.0) (31.5) (52.9)
Relative (17.2) (33.8) (60.6)
52 week high/low €5.1/€1.5

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free